Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
NEJM Evidence|May 28, 2024
Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure SyndromesTapan M Kadia, Meixian Huang, Naveen Pemmaraju, et al.
Blood Cancer Discovery|July 9, 2025
An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and ChemoresistanceCuijuan Han, Zhiping Zhang, Edie I Crosse, et al.
Nature Medicine|May 26, 2022
A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemiaAndy G X Zeng, Suraj Bansal, Liqing Jin, et al.
NPJ Precision Oncology|May 20, 2025
Multimodal spatial proteomic profiling in acute myeloid leukemiaChristopher P Ly, Ivo Veletic, Christopher D Pacheco, et al.
Haematologica|May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapseAlex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
Leukemia|July 6, 2026
Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase IIHannah C Beird, Sankaranarayanan Kannan, Jingjing Liu, et al.
American Journal of Hematology|June 19, 2023
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantationAlexandre Bazinet, Hagop Kantarjian, Naszrin Arani, et al.
Hemasphere|February 16, 2026
Outcomes of therapy-related non-core binding factor acute myeloid leukemia with venetoclax-based therapiesJayastu Senapati, Jennifer Croden, Guillermo Garcia-Manero, et al.
JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.
Pageof 10